Geoffrey Ku, MD, MBA, on Gastric and Esophageal Cancers: Expert Perspectives on Immunotherapy
2017 Gastrointestinal Cancers Symposium
Geoffrey Ku, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy drugs and the search for biomarkers that will help identify patients more likely to respond, not only to these medications, but to combinations of immunotherapies, other targeted treatments, chemotherapy drugs, and radiation.
Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.
Mark Talamonti, MD, of NorthShore University Health System, discusses the technical prerequisites for minimally invasive surgery in pancreatic cancers and the potential benefits to patients.
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.
Cathy Eng, MD, of The University of Texas MD Anderson Cancer Center, discusses management approaches to anal cancer, including the current standard of care, as well as novel approaches for locally advanced and metastatic disease.
Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
